Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

Comella, Pasquale; Frasci, G.; Panza, N.; Nicolella, Gianpaolo; Manzione, Luigi; Cataldis, Giuseppe De; Cioffi, R; Micillo, E; Lorusso, Vito; Bilancia, Domenico; Maiorino, L.; Piantedosi, Francovito; Mangiameli, A.; Gravina, Adriano; Lamberti, Alfredo; Lena, M. De; Comella, G.

doi:10.1016/s0169-5002(00)80258-5

Cited by 10 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platinum doublets have been found to be at least as effective and, in some cases, more effective than nonplatinum doublets [8]. Furthermore, three-drug regimens have been found to be no more effective than those with only two drugs [9][10][11][12][13][14][15]. Several two-drug platinum-based regimens have been compared directly, and no regimen stands out as more effective [16••].…”

Section: Introductionmentioning

confidence: 99%

Antimetabolites in the management of non-small cell lung cancer

Budde

Hanna²

2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Although chemotherapy has been shown to increase survival for patients with advanced-stage disease, survival benefits have been modest and come at the cost of significant toxicity. Treatment options in the second-line setting have been limited. Pemetrexed, a multitargeted antifolate, has activity as a single agent and as part of combination chemotherapy against NSCLC. As reported in a recent phase III clinical trial, survival outcomes in the second-line setting for patients treated with pemetrexed or docetaxel are similar. More importantly, major toxicity with the use of pemetrexed with vitamin B(12) and folate supplementation is far less than with docetaxel. Based on its single agent activity, ease of administration, and favorable toxicity profile, pemetrexed has the potential to be incorporated in various settings against NSCLC, including metastatic disease, as adjuvant therapy, and for locally advanced disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Antimetabolites in the management of non-small cell lung cancer

Budde

Hanna²

2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

show abstract

Chemotherapy in metastatic and locally advanced non‐small cell lung cancer

Spigel

Greco

2003

Seminars in Surgical Oncology

View full text Add to dashboard Cite

The majority of patients with non-small cell lung cancer have locally advanced and metastatic disease at diagnosis. Combination platinum-based chemotherapy is the standard treatment for patients with advanced disease who have a performance status of 0-1. Chemotherapy is superior to supportive care alone in terms of survival, palliation of symptoms, and in many studies, improving quality of life. Newer third generation therapies such as paclitaxel, docetaxel, vinorelbine, and gemcitabine have been proven effective as single agents with minimal toxicity, compared with supportive care alone. In combination with platinum, these agents produce higher response rates than older platinum-based regimens, are associated with additional survival benefits, and are generally more convenient and less toxic for patients. Newer nonplatinum doublets appear equivalent to newer platinum-regimens and have expanded the options available for patients. Targeted agents are promising and may soon offer patients more effective and less toxic therapies. Progress in treatment in the advanced setting has led to advances in the care of locally advanced disease. Combination chemoradiotherapy is a standard treatment for locally advanced disease, and studies with newer agents are in progress.

show abstract